Hoban CJ - Search Results

1

Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.

Schurek KN, Adam HJ, Siemens CG, Hoban CJ, Hoban DJ, Zhanel GG. Schurek KN, et al. Among authors: hoban cj. J Antimicrob Chemother. 2005 Oct;56(4):769-72. doi: 10.1093/jac/dki315. Epub 2005 Aug 26. J Antimicrob Chemother. 2005. PMID: 16126779

2

Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.

Adam HJ, Schurek KN, Nichol KA, Hoban CJ, Baudry TJ, Laing NM, Hoban DJ, Zhanel GG. Adam HJ, et al. Among authors: hoban cj. Antimicrob Agents Chemother. 2007 Jan;51(1):198-207. doi: 10.1128/AAC.00609-06. Epub 2006 Nov 6. Antimicrob Agents Chemother. 2007. PMID: 17088485 Free PMC article.

3

Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.

Smith HJ, Noreddin AM, Siemens CG, Schurek KN, Greisman J, Hoban CJ, Hoban DJ, Zhanel GG. Smith HJ, et al. Among authors: hoban cj. Antimicrob Agents Chemother. 2004 Sep;48(9):3630-5. doi: 10.1128/AAC.48.9.3630-3635.2004. Antimicrob Agents Chemother. 2004. PMID: 15328145 Free PMC article.

4

Mental health issues associated with foot complications of diabetes mellitus.

Hoban C, Sareen J, Henriksen CA, Kuzyk L, Embil JM, Trepman E. Hoban C, et al. Foot Ankle Surg. 2015 Mar;21(1):49-55. doi: 10.1016/j.fas.2014.09.007. Epub 2014 Sep 22. Foot Ankle Surg. 2015. PMID: 25682407

5

Prioritization in comparative effectiveness research: the CANCERGEN Experience.

Thariani R, Wong W, Carlson JJ, Garrison L, Ramsey S, Deverka PA, Esmail L, Rangarao S, Hoban CJ, Baker LH, Veenstra DL; Center for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN). Thariani R, et al. Among authors: hoban cj. Med Care. 2012 May;50(5):388-93. doi: 10.1097/MLR.0b013e3182422a3b. Med Care. 2012. PMID: 22274803 Free PMC article.

6

SWOG Cooperative Group biorepository resource: access for scientific research studies.

Hoban CJ, Franklin W, Kopecky KJ, Baker LH. Hoban CJ, et al. Clin Cancer Res. 2011 Aug 15;17(16):5239-46. doi: 10.1158/1078-0432.CCR-10-3138. Epub 2011 May 9. Clin Cancer Res. 2011. PMID: 21555374

7

From the lab to the clinic: integration of pharmacogenics into clinical development.

Hoban CJ. Hoban CJ. Pharmacogenomics. 2002 Jul;3(4):429-36. doi: 10.1517/14622416.3.4.429. Pharmacogenomics. 2002. PMID: 12164766 Free article. No abstract available.

8

The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis.

Cannella B, Hoban CJ, Gao YL, Garcia-Arenas R, Lawson D, Marchionni M, Gwynne D, Raine CS. Cannella B, et al. Among authors: hoban cj. Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10100-5. doi: 10.1073/pnas.95.17.10100. Proc Natl Acad Sci U S A. 1998. PMID: 9707607 Free PMC article.

9

Neuregulins as potential drugs for neurological disorders.

Marchionni MA, Kirk CJ, Isaacs IJ, Hoban CJ, Mahanthappa NK, Anton ES, Chen C, Wason F, Lawson D, Hamers FP, Canoll PD, Reynolds R, Cannella B, Meun D, Holt WF, Matthew WD, Chen LE, Gispen WH, Raine CS, Salzer JL, Gwynne DI. Marchionni MA, et al. Among authors: hoban cj. Cold Spring Harb Symp Quant Biol. 1996;61:459-72. Cold Spring Harb Symp Quant Biol. 1996. PMID: 9246474 Review. No abstract available.

10

The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter.

Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. Wagner BJ, et al. Among authors: hoban cj. EMBO J. 1990 Dec;9(13):4477-84. doi: 10.1002/j.1460-2075.1990.tb07898.x. EMBO J. 1990. PMID: 2176154 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page